Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech, an AI-focused TechBio company, announced the launch of its enhanced AI-Immunology platform with an updated EDEN model to expedite the development of novel vaccines. The updated model can predict toxin antigens more accurately, which is crucial for creating effective bacterial vaccines. This advancement is set to improve the speed and efficiency of vaccine discovery, leveraging AI to meet urgent medical needs.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
